Last week, Dr. Michelle Ghert presented the Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial at the European Musculo-Skeletal Oncology Society (EMSOS) with the goal of introducing the study to potential European investigators and discussing the team’s plan for international expansion. While in Athens, the PARITY team also met with European collaborators who have already expressed interest in participating in the trial to strategize country specific plans for study initiation. It is planned that at least 9 sites across Spain, the Netherlands, Austria, Sweden, Denmark, Finland, France and Italy by the end of the year.
The PARITY network is a collaboration that brings together experts in clinical trials, biostatistics, orthopaedic surgery, oncology, pharmacy, and research coordination. This renowned group is proving that orthopaedic oncology can lead transformational research programs around the world. The PARITY trial is the first ever multi-center randomized controlled trial in orthopaedic oncology.